Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms

NCT02628535 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT02628535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02628535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
Lead sponsor
MacroGenics
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2015
Completion date
November 25, 2019
Enrollment
67 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, breast cancer, clear cell renal cell carcinoma, colon cancer, melanoma, mesothelioma, non small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, soft tissue sarcoma, squamous cell carcinoma of the head and neck, thyroid cancer